Press Release: European Medicines Agency starts review of rosiglitazone-containing medicines

Author (Corporate)
Series Title
Series Details EMA/425166/2010 (9.7.10)
Publication Date 09/07/2010
Content Type

The European Medicines Agency (EMA), in July 2010, started a review of the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim, to determine whether new data on the risk of cardiovascular problems have an impact on their benefit-risk profile.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001050.jsp&mid=WC0b01ac058004d5c1
Related Links
BBC News, 6.9.10: Diabetes drug still available despite suspension advice http://www.bbc.co.uk/news/health-11170878
EMA: News, 8.8.10: CHMP meets to discuss Avandia and Pandemrix http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001110.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1
EMA: Press Release, 22.7.10: European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001062.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1
EMA: Press Release: EMA/585784/2010 ( 23.09.10): European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Subject Categories
Countries / Regions